Applied Therapeutics, Inc. – NASDAQ:APLT

Add to watchlist

$0.494

-0.35

-42.13%

Market closed

Open in about 4 hours

-84.63%

month

-84.63%

quarter

-72.83%

year

Market Cap	97.45M
Enterprise value	13.26M

P/E	-0.36
EV/Sales	N/A
EV/EBITDA	-0.10
Price/Sales	N/A
Price/Book	7.14
PEG ratio	N/A
EPS	-1.96

Revenue	N/A
EBITDA	-44.88M
Income	-193.56M
Revenue Q/Q	-98.21%
Revenue Y/Y	-104.47%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Applied Therapeutics Stock Forecast

M Q Y

Last Year

$4.5

Potential upside: 811.30%

Analysts Price target
Financials & Ratios estimates

Applied Therapeutics, Inc. (NASDAQ:APLT): Profit margin
Jun 2023	0	-29.57M
Sep 2023	0	-42.37M
Dec 2023	-667K	-37.67M	5649.03%
Mar 2024	190K	-83.93M	-44177.89%

Applied Therapeutics, Inc. (NASDAQ:APLT): Debt to assets
Jun 2023	43646000	47.98M	109.93%
Sep 2023	45195000	56.23M	124.44%
Dec 2023	54833000	71.97M	131.27%
Mar 2024	151234000	83.94M	55.5%

Applied Therapeutics, Inc. (NASDAQ:APLT): Cash Flow
Jun 2023	-16.45M	29.15M
Sep 2023	-14.72M	16.56M
Dec 2023	-17.00M	29.44M
Mar 2024	-18.91M	115.49M

Applied Therapeutics alternative data

Applied Therapeutics
Employees

Applied Therapeutics, Inc. (NASDAQ:APLT): Employee count
Aug 2023	26
Sep 2023	22
Oct 2023	22
Nov 2023	22
Dec 2023	22
Jan 2024	22
Feb 2024	22
Mar 2024	25
Apr 2024	25
May 2024	25
Jun 2024	26
Jul 2024	26

Applied Therapeutics
Hedge Funds Holdings Q1 2023

29.82% -11.18%

of APLT is owned by hedge funds

19 -17

hedge funds hold APLT stock

11.27M -8.39M

shares is hold by hedge funds

APLT hedge funds holdings changes

Applied Therapeutics
Insider Trading

Applied Therapeutics, Inc. (NASDAQ:APLT): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	0	136284
Oct 2023	0	155000
Nov 2023	0	426516
Dec 2023	30000	0
Mar 2024	0	506975
Jun 2024	0	400778
Aug 2024	0	813225

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	22 Aug 2024	FUNTLEYDER LESLIE D. director, officer: Chief Financial Of.. director, officer: Chief Financ..	Common Stock	13,530	$5.83	$78,880
Sale	22 Aug 2024	PERFETTI RICCARDO officer: Chief Me..	Common Stock	22,681	$5.83	$132,230
Sale	14 Aug 2024	SHENDELMAN SHOSHANA director, officer..	Common Stock	119,591	$5.93	$709,175
Sale	13 Aug 2024	SHENDELMAN SHOSHANA director, officer..	Common Stock	357,423	$6.18	$2,208,874
Sale	12 Aug 2024	SHENDELMAN SHOSHANA director, officer..	Common Stock	300,000	$5.98	$1,794,000
Sale	6 Jun 2024	SHENDELMAN SHOSHANA director, 10 perc..	Common Stock	61,795	$4.32	$266,954
Sale	6 Jun 2024	PERFETTI RICCARDO officer: Chief Me..	Common Stock	22,003	$4.32	$95,053
Sale	6 Jun 2024	FUNTLEYDER LESLIE D. director, officer: Chief Financial Of.. director, officer: Chief Financ..	Common Stock	16,980	$4.32	$73,354
Sale	5 Jun 2024	ALEXANDRIA REAL ESTATE EQUITIES, INC. 10 percent owner 10 percent owner	Common Stock	150,000	$4.24	$636,000
Sale	4 Jun 2024	ALEXANDRIA REAL ESTATE EQUITIES, INC. 10 percent owner 10 percent owner	Common Stock	150,000	$4.21	$631,500

APLT insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY Filling date: 7 Apr 2022 Issue date: 21 Jul 2022	7 Apr 2022	21 Jul 2022
Application	Application METHODS FOR TREATING CUTANEOUS AGING Filling date: 12 Feb 2020 Issue date: 10 Mar 2022	12 Feb 2020	10 Mar 2022
Application	Application INHIBITORS OF ALDOSE REDUCTASE Filling date: 29 Sep 2021 Issue date: 20 Jan 2022	29 Sep 2021	20 Jan 2022
Application	Application COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA Filling date: 27 Jul 2018 Issue date: 23 Jul 2020	27 Jul 2018	23 Jul 2020
Application	Application ALDOSE REDUCTASE INHIBITORS AND USES THEREOF Filling date: 17 Apr 2018 Issue date: 30 Apr 2020	17 Apr 2018	30 Apr 2020

Applied Therapeutics
Executives

Insider	Age	Compensation
Dr. Shoshana Shendelman Ph.D. (1979) Chair of the Board of Directors, Founder, Pres, Chief Executive Officer & Sec.	46	$895,120
Dr. Riccardo Perfetti (1959) Chief Medical Officer	66	$672,140
Dr. Charles Silberstein M.D., CFA (1971) Chief Financial Officer & Head of Bus. Devel.	54	$378,200

Applied Therapeutics
Latest News

Saturday, 28 December 2024
22:47	Levi & Korsinsky Notifies Shareholders of Applied Therapeutics, Inc.(APLT) of a Class Action Lawsuit and an Upcoming Deadline	accesswire.com
20:37	February 18, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against APLT	accesswire.com
18:01	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit - APLT	accesswire.com
11:30	Applied Therapeutics Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm	accesswire.com
10:00	ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT	globenewswire.com
07:40	APPLIED CLASS ACTION LAWSUIT: Applied Therapeutics, Inc. Investors with Losses are Notified of February 18 Deadline in Securities Fraud Class Action – Contact BFA Law (NASDAQ:APLT)	globenewswire.com
Friday, 27 December 2024
16:15	APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	accesswire.com
15:56	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - APLT	prnewswire.com
15:45	Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT	accesswire.com
15:38	APLT CLASS ACTION ALERT: Applied Therapeutics, Inc. Investors are Notified of the Ongoing Class Action Lawsuit - Contact BFA Law before February 18 Court Deadline	accesswire.com
14:30	Applied Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - APLT	accesswire.com
14:10	APLT Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Applied Therapeutics, Inc. (APLT) - Contact Kessler Topaz Meltzer & Check, LLP	globenewswire.com
13:30	Contact Levi & Korsinsky by February 18, 2025 Deadline to Join Class Action Against Applied Therapeutics, Inc. (APLT)	accesswire.com
13:00	The Schall Law Firm Invites Shareholder Contributions To A Securities Fraud Case Against Applied Therapeutics, Inc.	accesswire.com
12:15	Applied Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT	accesswire.com
11:45	APLT INVESTOR DEADLINE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	prnewswire.com
08:00	APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	accesswire.com
07:30	Shareholders that lost money on Applied Therapeutics, Inc. (APLT) should contact Levi & Korsinsky about pending Class Action - APLT	accesswire.com
07:00	APLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!	accesswire.com
05:45	Applied Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT	prnewswire.com
00:30	Shareholders that lost money on Applied Therapeutics, Inc.(APLT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More	accesswire.com
Thursday, 26 December 2024
21:00	APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Applied Therapeutics, Inc. and Encourages Investors to Contact the Firm	globenewswire.com
17:39	Faruqi & Faruqi Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 – APLT	globenewswire.com
15:18	APLT DEADLINE NOTICE: A Class Action was filed on behalf of Applied Therapeutics, Inc. Shareholders - Contact BFA Law if You Lost Money before Court Deadline (APLT)	accesswire.com
13:45	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - APLT	accesswire.com
13:15	Applied Therapeutics Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm	accesswire.com
12:45	Investors who lost money on Applied Therapeutics, Inc. (APLT) should contact Levi & Korsinsky about pending Class Action - APLT	accesswire.com
12:15	Contact Levi & Korsinsky by February 18, 2025 Deadline to Join Class Action Against Applied Therapeutics, Inc. (APLT)	accesswire.com
11:30	Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT	accesswire.com
11:00	Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT	accesswire.com

Frequently Asked Questions (FAQ)

What's the price of Applied Therapeutics stock today?

One share of Applied Therapeutics stock can currently be purchased for approximately $0.49.
When is Applied Therapeutics's next earnings date?

Unfortunately, Applied Therapeutics's (APLT) next earnings date is currently unknown.
Does Applied Therapeutics pay dividends?

No, Applied Therapeutics does not pay dividends.
How much money does Applied Therapeutics make?

Applied Therapeutics has a market capitalization of 97.45M.
What is Applied Therapeutics's stock symbol?

Applied Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "APLT".
What is Applied Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Applied Therapeutics?

Shares of Applied Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Applied Therapeutics's key executives?
Applied Therapeutics's management team includes the following people:
- Dr. Shoshana Shendelman Ph.D. Chair of the Board of Directors, Founder, Pres, Chief Executive Officer & Sec.(age: 46, pay: $895,120)
- Dr. Riccardo Perfetti Chief Medical Officer(age: 66, pay: $672,140)
- Dr. Charles Silberstein M.D., CFA Chief Financial Officer & Head of Bus. Devel.(age: 54, pay: $378,200)
Is Applied Therapeutics founder-led company?

Yes, Applied Therapeutics is a company led by its founder Dr. Shoshana Shendelman Ph.D..
How many employees does Applied Therapeutics have?

As Jul 2024, Applied Therapeutics employs 26 workers, which is 4% more then previous quarter.
When Applied Therapeutics went public?

Applied Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 14 May 2019.
What is Applied Therapeutics's official website?

The official website for Applied Therapeutics is appliedtherapeutics.com.
Where are Applied Therapeutics's headquarters?

Applied Therapeutics is headquartered at 545 Fifth Avenue, New York, NY.
How can i contact Applied Therapeutics?

Applied Therapeutics's mailing address is 545 Fifth Avenue, New York, NY and company can be reached via phone at +212 2209226.
What is Applied Therapeutics stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Applied Therapeutics in the last 12 months, the avarage price target is $4.5. The average price target represents a 811.30% change from the last price of $0.49.

Applied Therapeutics, Inc.

appliedtherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

+212 2209226

545 Fifth Avenue
New York, NY 10017

CIK: 0001697532
ISIN: US03828A1016
CUSIP: 03828A101